There were 12 instances of severe dengue: 1 in the vaccine group and 11 in the control group . Efficacy against severe dengue was 95.5 percent following the first injection and 91.7 percent after the third injection. Eleven of the patients with severe VCD had dengue hemorrhagic fever : 1 patient in the vaccine group and 10 sufferers in the control group . Efficacy against dengue hemorrhagic fever was 95.0 percent following the first injection and 90.0 percent after the third injection. The one episode of dengue hemorrhagic fever in the vaccine group was categorized as severe based on laboratory results only; the kid was not hospitalized.At week 13, there were no relevant differences among groupings in corticotropin clinically, thyrotropin, prolactin, or aminotransferase levels. There were transient raises in mean levels of total cholesterol during treatment. There were no significant between-group differences in blood pressure and heartrate at week 13 . At week 13, mean endometrial thicknesses were 9.4 mm in the combined group receiving 5 mg of ulipristal acetate, 10.7 mm in the combined group receiving 10 mg of ulipristal acetate, and 5.1 mm in the group receiving leuprolide acetate .